The primary objective: association study of characteristics of tumoral microenvironment and immunity of digestive cancers with patients' overall survival (OS).
Carcinoma of colorectal, pancreatic, biliary tract or gastro-oesophageal, or neuroendocrine digestive tumors with cytologically or histologically proven, regardless of the stage;
Diagnosis between 1998 and 2030;
Be >/= 18 years;
Have obtained signed informed consent (exemption for dead patients);
Patient under tutoraship or curatorship;
Foreign patient under AME schema, a medical help from the state in France;
Pregnant or breastfeeding women (for prospective study);
Any clinical, psychological or social reason which should influence patient compliance with protocol, according to investigator;
10
Treatment groupsSee each treatment group below.